

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

1. (Currently Amended) A method for inducing apoptosis in a tumor cell, comprising:
contacting a tumor cell with an amount of a metabolic modifying agent, which when exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to increase the mitochondrial membrane potential in the tumor cell, wherein the metabolic modifying agent is selected from the group consisting of glucose, an MHC class II HLA-DP/DQ ligand, guanosine diphosphate (GDP), sodium acetate, and a combination of phorbol myristate acetate in combination with and ionomycin, ~~GDP, sodium acetate, UCP antisense, dominant negative UCP, and staurosporine,~~ and
contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent effective for inducing apoptosis in the tumor cell, wherein the apoptotic chemotherapeutic agent is selected from the group consisting of methotrexate, 5-fluorouracil, floxuridine, cytarabine, azauridine, Interferon α , cisplatin, carboplatin, TAXOL™, and ADRIAMYCIN™.
2. (Currently Amended) The method of claim 1, wherein the apoptotic chemotherapeutic agent is selected from the group consisting of ADRIAMYCIN™, cytarabine, ~~doxorubicin,~~ and methotrexate.
3. (Original) The method of claim 1, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered simultaneously.
4. (Original) The method of claim 1, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered locally.

5. (Original) The method of claim 1, wherein the tumor cell is resistant to the apoptotic chemotherapeutic agent.

6. (Currently Amended) A method for inducing apoptosis in a tumor cell, comprising:
contacting a tumor cell with an amount of a metabolic modifying agent, which when
exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to
increase the mitochondrial membrane potential in the tumor cell, wherein the metabolic modifying
agent is selected from the group consisting of glucose, an MHC class II HLA-DP/DQ ligand,
guanosine diphosphate (GDP), sodium acetate, and a combination of phorbol myristate acetate and
ionomycin, and staurosporine, and
contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent
selected from the group consisting of methotrexate, pyrimidine analogs, purine analogs, cisplatin,
carboplatin, TAXOL™, and tamoxifen effective for inducing apoptosis in the tumor cell The
method of claim 1, wherein the tumor cell is sensitive to the apoptotic chemotherapeutic agent, and
wherein the amount of metabolic modifying agent is effective to increase mitochondrial membrane
potential and the amount of apoptotic chemotherapeutic agent is effective to inhibit the proliferation
of the tumor cell when the mitochondrial membrane potential is increased.

7. (Currently Amended) A method for inducing apoptosis in a tumor cell, comprising:
contacting a tumor cell with an amount of a metabolic modifying agent, which when
exposed to a cell causes coupling of electron transport and oxidative phosphorylation, effective to
increase the mitochondrial membrane potential in the tumor cell, and
contacting the tumor cell with an amount of an apoptotic chemotherapeutic agent
effective for inducing apoptosis in the tumor cell, wherein the apoptotic chemotherapeutic agent is
selected from the group consisting of cytarabine, ~~doxorubicin~~, and methotrexate.

8. (Currently Amended) The method of claim 7, wherein the metabolic modifying agent
is selected from the group consisting of glucose, an MHC class II HLA-DP/DQ ligand, ~~phorbol~~

~~myristate acetate in combination with ionomycin~~, GDP, sodium acetate, UCP antisense, dominant negative UCP, ~~and staurosporine~~ and a combination of phorbol myristate acetate with ionomycin.

9. (Original) The method of claim 7, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered simultaneously.

10. (Original) The method of claim 7, wherein the metabolic modifying agent and the apoptotic chemotherapeutic agent are administered locally.

11. (Original) The method of claim 7, wherein the tumor cell is resistant to the apoptotic chemotherapeutic agent.